Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
By Sean McSweeney bio
Does your orthopedic billing company charge a percentage of collections for their coding and billing…
From - Diagnostic Testing & Emerging Technologies
Use of upfront next-generation sequencing (NGS) testing at diagnosis of patients with metastatic non-small-cell lung cancer (mNSCLC) is…
By Dan Scungio, MT (ASCP), SLS, CQA (ASQ) bio
Sometimes when I am talking about lab safety and the topic turns to ergonomics, I get an unusual reaction from the audience…
From - Diagnostic Testing & Emerging Technologies
The National Comprehensive Cancer Network genetic testing criteria for hereditary cancer miss almost one in five at-risk for…
From - Diagnostic Testing & Emerging Technologies
A single urine spot sample can be used to objectively screen for nonadherence to diabetes medications in the…
From - Diagnostic Testing & Emerging Technologies
The hope of developing a single blood test capable of detecting multiple types of early-stage cancer is…
From - Diagnostic Testing & Emerging Technologies
Raising the laboratory threshold for identifying potential urinary tract infections (UTIs) may prevent…
By Leora Borgenicht bio
Before the healthcare industry can ambitiously transform to offer more accurate and personalized patient care, certain stepping stones must…